Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||PTPN11 mutant|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PTPN11 mutant||juvenile myelomonocytic leukemia||not applicable||N/A||Clinical Study||Emerging||In two clinical studies, PTPN11 mutations were frequently identified in patients with juvenile myelomonocytic leukemia and were found to be associated with poor survival (PMID: 19047918, PMID: 21901340), suggesting that this may serve as a future prognostic biomarker.||21901340 19047918|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03190915||Phase II||Trametinib||Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia||Recruiting|
|NCT03613532||Phase I||Busulfan + Fludarabine + Venetoclax||Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN||Recruiting|